EGFR and neoplasm: Of note, tumour ECs are characterised by a pro-angiogenic phenotype with the upregulation of a range of angiogenesis-related tyrosine kinase receptors like VEGF receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2), platelet-derived endothelial growth factor receptor (PDGFR) and endothelial growth factor receptor (EGFR), which specifically inhibit tumour immunity [22,23,24].